Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22986Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:29:39Z | - |
| dc.date.available | 2015-11-24T19:29:39Z | - |
| dc.identifier.issn | 1948-5182 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22986 | - |
| dc.rights | Default Licence | - |
| dc.title | Combination drug treatment in patients with non-alcoholic fatty liver disease | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.4254/wjh.v2.i4.139 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/21160985 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2010 | - |
| heal.abstract | Non-alcoholic fatty liver disease (NAFLD) includes simple steatosis, a benign condition, and non-alcoholic steatohepatitis, a condition that beyond TG accumulation also includes necroinflammation and fibrosis. An association between NAFLD and cardiovascular disease (CVD) has been recently suggested. NAFLD patients usually have an increased CVD risk profile. NAFLD is also associated with metabolic syndrome (MetS) and is considered as the hepatic component of MetS by some authors. Currently, the only established treatment of NAFLD is gradual weight loss. However, multifactorial treatment of NAFLD risk factors may be needed to reduce the increased CVD risk of NALFD patients. Drug combinations that include antiobesity drugs (such as orlistat and sibutramine) and target CVD risk factors may be a good approach to NAFLD patients. Our group has investigated the orlistat-fenofibrate combination treatment in obese patients with MetS and the orlistat-ezetimibe and sibutramine-antihypertensive combination treatment in obese patients with hyperlipidaemia with promising results in CVD risk factor reduction and improvement of liver function tests. Small studies give promising results but double-blind, randomized trials examining the effects of such multifactorial treatment in hard CVD endpoints in NAFLD patients are missing. | en |
| heal.journalName | World J Hepatol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Elisaf-2010-combination drug treatment.pdf | 567.17 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
